On 22 June 2026, Munich sweltered in midsummer temperatures of 32 degrees Celsius. In the perfectly air-conditioned premises of the EY wavespace Munich, a pioneering event format celebrated its exclusive premiere: Around 50 hand-picked decision-makers – including a select circle of investors, scientists, leading experts, as well as the annual partners of Impact Life Sciences and VentureCapital Magazin – gathered for the ‚invite-only‘ launch of the first ‚Impact Life Sciences Deep Dive 2026‘.
The programme offered a tripartite approach, bridging the national status quo with regional strengths and global opportunities. Following welcoming remarks by Karin Hofelich (Life Science Lead), Mathias Renz (Head of VentureCapital Magazin), and Klaus Ort (Partner/Principal, EY), the EY German Biotechnology Report 2026 and the BioM annual report ‚Biotech in Bavaria 2025/26‘ set the scene. The core finding: Excellent domestic science all too often encounters a chronic funding deficit in later stages within Europe.
Press release from "VentureCapital Magazin" dated 25 June 2026